Watch Ticker

Avalo Therapeutics, Inc. Common Stock

Go to Avalo Therapeutics, Inc. Common Stock Website

$8.51

-0.46 (-5.18%)

Live

Previous Close

$8.97

Day Range

$8.25 - $9.2

Previous Day Range

$7.95 - $9.4099

Market Cap

$85.4 million USD

Day Vol.

1.2 million

Previous Day Vol.

247647

Currency

USD

Primary Exchange

Nasdaq

Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also incl...

Community

0 posts discussing

0

Watchers

0

Visitors

Recent News

N/A - Avalo Therapeutics to Participate in Upcoming Investor Conferences

Avalo Therapeutics, a clinical-stage biotechnology company, announced its participation in upcoming investor conferences to discuss its lead asset AVTX-009, a monoclonal antibody targeting inflammatory diseases.

Related tickers: AVTX.

Read Full Article

N/A - Avalo Reports First Quarter 2025 Financial Results and Recent Business Updates

Avalo Therapeutics announced progress in its Phase 2 LOTUS trial for hidradenitis suppurativa, with topline data expected in 2026. The company has sufficient cash runway into 2027, with potential to extend into 2028. Avalo is carefully evaluating the timing of additional development activities to preserve capital.

Related tickers: AVTX.

Read Full Article

Trending Tickers

Please sign in to view